1. Apremilast and its role in psoriatic arthritis, G;Sandhu;Ital. Dermatol. Venereol.,2020
2. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3);Edwards;Ann. Rheum. Dis.,2016
3. Pathogenesis of psoriatic arthritis, Best practice & research;Stober;Clin. Rheumatol.,2021
4. The pathogenesis of psoriatic arthritis;Veale;Lancet (London, England),2018
5. Pathophysiology, clinical presentation, and treatment of psoriasis: a review;Armstrong;JAMA,2020